IDEAYA Biosciences
An oncology company, develops cancer therapeutics.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| investor investor investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | $302m | Post IPO Equity |
| Total Funding | 000k | ||
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 43 % | 82 % | (54 %) | (70 %) | 109 % | 256 % | 223 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (180 %) | (123 %) | (558 %) | (4616 %) | (2219 %) | (552 %) | (63 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (178 %) | (115 %) | (483 %) | (3921 %) | (2001 %) | (564 %) | (153 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 208 % | 176 % | 554 % | 4210 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
IDEAYA Biosciences is a precision medicine company specializing in oncology, dedicated to discovering and developing targeted therapeutics for specific patient populations identified through molecular diagnostics. The company integrates expertise in identifying and validating translational biomarkers with small molecule drug discovery to select patient populations most likely to benefit from its therapies. IDEAYA operates in the biotechnology and pharmaceutical market, primarily serving healthcare providers and patients with specific cancer types. The business model revolves around research and development, clinical trials, and eventual commercialization of its therapeutic products. Revenue is generated through partnerships, licensing agreements, and sales of approved drugs.
Keywords: oncology, precision medicine, targeted therapeutics, molecular diagnostics, translational biomarkers, small molecule drugs, cancer treatment, biotechnology, clinical trials, healthcare.